<strong>Creativity</strong> and <strong>Innovation</strong><br /> for the patient Development of <strong>new therapies</strong> and <br /><strong>treatments</strong> to improve citizens health <strong>Internationally renowned</strong><br /> biomedical research

Creativity and Innovation
for the patient

Development of new therapies and
treatments to improve citizens health

Internationally renowned
biomedical research


Ignacio Larráyoz

Ignacio Larráyoz

Ignacio Larráyoz

Email: ilarrayoz@riojasalud.es

Phone: + 34 941 278 770 (Ext.:89878)


Dr. Larráyoz graduated in Pharmacy at the University of Navarra in 1999. He later joined the Department of Physiology and Nutrition as an assistant professor to perform his doctoral thesis in the laboratory of Dr. Mª Pilar Lostao. There, he characterized various nucleoside transporters by electrophysiology techniques. After obtaining its doctorate in 2004, he completed a postdoctoral stay in that department.

In 2005 he joined the laboratory of Dr. Juan M. Saavedra (NIMH / NIH, Bethesda) as a postdoctoral researcher to characterize the inflammatory pathways and toxicity involved in the lipopolysaccharide (LPS) response.

In 2008 he joined the laboratory of Dr. Ignacio Rodríguez at the National Eye Institute (NEI / NIH) to explore the pro-inflammatory and pro-angiogenic pathways of oxidized lipids in the pathogenesis of age-related macular degeneration (AMD).

In 2010, he returned to Logroño to work in the laboratory of Dr. Alfredo Martínez (CIBIR) to participate in a double-blind, randomized, unicentric phase II study comparing oral doxycycline versus placebo in patients with pterygium. In parallel, the mechanisms exerted by doxycycline were analyzed using mass generation sequencing technologies and bioinformatic methods.

Since 2012 he is accredited as Professor Titular by ANECA and is Associate Professor of the School of Nursing of the University of La Rioja where he teaches Biochemistry and Physiology.

He is currently the Principal Investigator of the Biomarker and Molecular Signaling Unit at CIBIR, applying the latest sequencing and molecular biology techniques to discover new biomarkers in high impact diseases.

Dr. Larráyoz received in 2005 the prestigious Visiting Fellow Award for his postdoctoral stays in the USA and recently obtained a “Contrato Miguel Servet” from the Institute of Health Carlos III. He has published more than 30 articles in national and international journals and two book chapters. He has also participated in 4 international patents.






11 April 2017


Biomarkers and Molecular Signaling


La Rioja Crece con Europa. Programa Operativo FEDER de La Rioja, 2014-2020

Unesco, Organización de las naciones unidas para la educación la ciencia y la cultura. Centro Nacional de Documentación y Bioética

Diploma de compromiso con la excelencia

Etiqueta de calificación energética

ISO 14001:2015